Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 6:26 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SYRS 6.52 +0.38(6.19%)
Will SYRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SYRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRS
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
SYRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Other News for SYRS
TD Cowen Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)
Buy Rating Affirmed: Syros Pharmaceuticals’ Promising Tamibarotene for MDS Treatment
JMP Securities Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
Syros Pharmaceuticals’ Shareholders Approve Key Updates and Elections